Do your own DD. GLTA!
Do your own DD. GLTA!
Fourth Quarter 2013 Revenues Increased 42.1% to $3.0 Million; Full-Year 2013 Revenues Increased 32.5% to $11.2 Million
Cost Reduction Initiative in Place to Reduce Expenses in 2014
RiT Technologies Ltd. (Nasdaq:RITT), the leader in intelligent infrastructure management and the developer of an innovative indoor optical wireless technology solution, announced today its unaudited financial results for the fourth quarter and full year ended December 31, 2013.
Highlights for the Fourth Quarter 2013
-- Revenues for the fourth quarter of 2013 increased by 42.1% to $3.0 million, compared with $2.1 million for the fourth quarter of 2012
-- Gross margin for the fourth quarter of 2013 improved to 8.6% (including inventory write-offs of $0.6 million), compared to -6.0% for the fourth quarter of 2012 (including inventory write-offs of $0.8 million)
-- Net loss for the fourth quarter of 2013 (including approximately $240,000 in stock-based compensation expenses) was $3.3 million, or $0.30 per (basic and diluted) share, compared with a net loss of $2.9 million, or $0.44 per (basic and diluted) share in the fourth quarter of 2012 (including approximately $46,000 in stock-based compensation expenses)
Highlights for the Full Year 2013
-- Revenues for the full year 2013 increased by 32.5% to $11.2 million, from $8.4 million for full year 2012
-- Gross margin for full year 2013 improved to 30% (including inventory write-offs of $0.6 million), from 16% in 2012 (including inventory write-offs of $0.8 million)
Vanity press comes at a cost. 8^)
IntelGenx has previously announced a successful a pre-NDA meeting with the FDA following the completion of a bioequivalency study demonstrating that its oral film product is bioequivalent with Maxalt MLT®, a leading branded anti-migraine product manufactured by Merck. According to Merck's most recent annual report, sales of Maxalt® were $638 million in 2012. The thin-film formulation of Rizatriptan has been developed in accordance with the co-development and commercialisation agreement with RedHill (NASDAQ: RDHL) (TASE: RDHL) using IntelGenx' proprietary immediate release "VersaFilm™" drug delivery technology.
Again, I concur with Sarah. And although it may disturb your comfort level to learn that (1) I am not Sarah, and (2) I have never shorted a stock in my life…
that this is not about being "right" or "wrong", it is merely an observation. I wish you continued success.
Stproz, I'm with you. Better to take a profit and know you have it than risking a Monday down-draft, especially since FCEL is going up on NO NEWS. Granted, the rally extended through this point on Monday, however, no one knew that this would continue. Congrats on your gains; and of course, congrats to those who continue to hold and benefit.
Sorry you must "eat-crow" today. Guess hind-site is always 20/20. LOL!
As surmised on 02/21/14… the Ukraine conflict is sending the jitters throughout the market. Gold is a shoe-in. Hold on folks!
You guys are feeling sanguine at the moment because it's gone up. So it is understandable. That being said, Sarah's point is well taken. Over-sold it is.
not bashing. Just watch and learn.
Actually it's time for a "breakdown". WAY over-bought on no real news. It's gotten sympathy points from PLUG, nothing more. The reversal is now. (JMO, of course).
It was great ride up. On the sidelines for now. May jump back in after the retrace. GLTA!
Admisitration, absorption and metabolization is the issue. Otherwise there would not be oral, intramuscular, topical, subcutaneous, intranasal, intravenous, nebulized and sublingual administration routes for medications. Capice?
This is a gold mine. Accept it or invest in something else.